Clinical trials
catalyst calendar across sponsors →Studies where CSTL is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
5 observational
Held by 11 tracked-famous managers (Qube Research & Technologies Ltd, RENAISSANCE TECHNOLOGIES LLC, Point72 Asset Management, L.P., CITADEL ADVISORS LLC, MILLENNIUM MANAGEMENT LLC, +6 more) · FINRA short interest 3.2 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 22 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis FlaresNCT07645820observationalRelationship between skin measurements and subsequent atopic dermatitis flares | — | Recruiting | Device: Nevisense electrical impedance spectroscopy | Atopic Dermatitis | 450 | 2027-04-01 | in 225 d | 2026-06-12 |
| 5 Year Registry Study to Track Clinical Application of DecisionDx-UM Assay Results and Associated Patient OutcomesNCT02376920observationaldocumentation of clinical application of results obtained from DecisionDx-UM multi-gene assay | — | Completed | — | Uveal Melanoma | 93 | Apr 2022actual | — | 2022-05-16 |
| Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient OutcomesNCT02355587observationalAdjusted surveillance regimen | — | Terminatedsponsor's stated reason: Study goals were met with smaller that expected study cohort. Last patient completed the study June 201 | — | Cutaneous Melanoma | 72 | Jul 2021actual | — | 2021-10-08 |
| 5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay ResultsNCT02355574observationalAdjusted surveillance regimen | — | Terminatedsponsor's stated reason: Study endpoints completed with lower than anticipated enrollment. Last patient enrolled completed final visit February 2021. | — | Cutaneous Melanoma | 301 | Feb 2021actual | — | 2021-10-08 |
| Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein Expression AssaysNCT02407561observationalValidate the proprietary rectal and anal carcinoma immunohistochemistry protocols under CLIA compliant SOPs, in order to predict response to pre-operative chemoradiation treatment for patients with rectal/ anal carcinoma. | — | Terminatedsponsor's stated reason: Futility - unable to secure sites and samples for participation | — | Rectal Adenocarcinoma, Anal Adenocarcinoma, Anal Squamous Cell Carcinoma | 3 | Jul 2016actual | — | 2018-01-25 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19